This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | MicrobiomeTrials
← Back to trials NCT06649812
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2025-10-07Est. Completion: 2028-09-01
Enrollment target: 120 participantsLocations Banner University Medical Center - Tucson, Tucson, Arizona, United States University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States Cedars-Sinai Medical Center, Los Angeles, California, United States Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States Yale University, New Haven, Connecticut, United States Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States Northwestern University, Chicago, Illinois, United States Carle at The Riverfront, Danville, Illinois, United States Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States Carle Physician Group-Effingham, Effingham, Illinois, United States Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States Northwestern Medicine Glenview Outpatient Center, Glenview, Illinois, United States Other microbiome trials you might be interested in Lymphoma Leukemia
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
Duarte, United States Completed Aug 25, 2026
Recurrent Diffuse Large B-Cell Lymphoma Recurrent Grade 3b Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States
Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
Carle BroMenn Medical Center, Normal, Illinois, United States
Carle Cancer Institute Normal, Normal, Illinois, United States
Northwestern Medicine Oak Brook, Oak Brook, Illinois, United States
Northwestern Medicine Orland Park, Orland Park, Illinois, United States
Memorial Hospital East, Shiloh, Illinois, United States
Carle Cancer Center, Urbana, Illinois, United States
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
Northwest Cancer Center - Crown Point, Crown Point, Indiana, United States
Northwest Oncology LLC, Dyer, Indiana, United States
Saint Mary Medical Center, Hobart, Indiana, United States
Saint Catherine Hospital, Indianapolis, Indiana, United States
The Community Hospital, Munster, Indiana, United States
Women's Diagnostic Center - Munster, Munster, Indiana, United States
Northwest Cancer Center - Valparaiso, Valparaiso, Indiana, United States
Mary Greeley Medical Center, Ames, Iowa, United States
McFarland Clinic - Ames, Ames, Iowa, United States
McFarland Clinic - Boone, Boone, Iowa, United States
Mercy Hospital, Cedar Rapids, Iowa, United States
Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States
McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, United States
McFarland Clinic - Jefferson, Jefferson, Iowa, United States
McFarland Clinic - Marshalltown, Marshalltown, Iowa, United States
Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States
Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
Essentia Health Cancer Center, Duluth, Minnesota, United States
Essentia Health Hibbing Clinic, Hibbing, Minnesota, United States
Essentia Health Sandstone, Sandstone, Minnesota, United States
Essentia Health Virginia Clinic, Virginia, Minnesota, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Siteman Cancer Center-South County, St Louis, Missouri, United States
Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
Community Hospital of Anaconda, Anaconda, Montana, United States
Billings Clinic Cancer Center, Billings, Montana, United States
Bozeman Health Deaconess Hospital, Bozeman, Montana, United States
Benefis Sletten Cancer Institute, Great Falls, Montana, United States
Logan Health Medical Center, Kalispell, Montana, United States
Community Medical Center, Missoula, Montana, United States
Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States
Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States
Aultman Health Foundation, Canton, Ohio, United States
University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Providence Newberg Medical Center, Newberg, Oregon, United States
Providence Willamette Falls Medical Center, Oregon City, Oregon, United States
Providence Portland Medical Center, Portland, Oregon, United States
Providence Saint Vincent Medical Center, Portland, Oregon, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
University of Vermont Medical Center, Burlington, Vermont, United States
University of Vermont and State Agricultural College, Burlington, Vermont, United States
University of Virginia Cancer Center, Charlottesville, Virginia, United States
VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States
Swedish Medical Center-First Hill, Seattle, Washington, United States
Duluth Clinic Ashland, Ashland, Wisconsin, United States
Mercyhealth Hospital and Cancer Center - Janesville, Janesville, Wisconsin, United States
Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States
Froedtert and MCW Moorland Reserve Health Center, New Berlin, Wisconsin, United States
Drexel Town Square Health Center, Oak Creek, Wisconsin, United States
ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States
Essentia Health-Spooner Clinic, Spooner, Wisconsin, United States
Essentia Health Saint Mary's Hospital - Superior, Superior, Wisconsin, United States
UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States
Froedtert West Bend Hospital/Kraemer Cancer Center, West Bend, Wisconsin, United States Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Grade 3b Follicular Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib …
Minneapolis, United States Est. completion Aug 31, 2027